Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
CELU Stock — Celularity Inc
Celularity Inc (CELU)
Updated October 16, 2026.
CELU is a Stock. Total return is -98.7% over the past 7.2 years, 287.3 points behind SPY at 188.6%.
Celularity Inc. is a cellular and regenerative medicine company developing off-the-shelf cell therapy products and treatments for aging-related diseases, with particular focus on conditions like Crohn's disease, multiple sclerosis, and diabetic foot ulcers. The company operates through three segments: cell therapy development, degenerative disease treatment, and BioBanking services including the LifebankUSA cord blood and tissue storage business. Celularity does not currently distribute dividends and operates as a clinical-stage biopharmaceutical company, making it suitable primarily for growth-oriented investors with tolerance for the risks typical of early-stage therapeutic development companies.
CELU performance versus SPY
Price and return data through 2026-10-16.
Total return is -98.7% over the past 7.2 years, 287.3 points behind SPY at 188.6%. Over the past year its total return — price change plus distributions reinvested — is -41.3%. Its deepest 1-year drawdown was 71.9%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -3.1% | — |
| 3M | 62.7% | — |
| 6M | 0.8% | — |
| YTD | 12.6% | — |
| 1Y | -41.3% | — |
| 2Y CAGR | — | -33.00% |
| 3Y CAGR | — | -27.60% |
| 5Y CAGR | — | -55.50% |
| Since inception (7.2 years) | -98.7% | -45.50% |
CELU key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 08/08/2019
- Distribution frequency
- None
- Last close
- $1.25 (as of 2026-10-16)
- Market cap
- $40,562,209
- Average volume
- 63935.0
- Beta
- 0.797
- Payout ratio
- 0.0%
- EPS
- $-3.16
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
CELU risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 71.9%.
Who may consider CELU — and who may not
It is a weaker fit for investors who need monthly cash flow (CELU does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on CELU
Frequently asked questions
Does CELU pay monthly?
No. CELU does not currently distribute.
When does CELU pay a dividend?
CELU does not currently distribute.
How has CELU performed?
Total return is -98.7% over the past 7.2 years, 287.3 points behind SPY at 188.6%. Over the past year its total return — price change plus distributions reinvested — is -41.3%. Its deepest 1-year drawdown was 71.9%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.